本网站由山东省血友病联谊会、山东省血友病关怀工作室主办 宗旨:全面提高山东省血友病病人的生存质量!
 设为首页
 加入收藏
 联系我们
| 网站首页 | 患者登记 | 雁过留声 | 测网速 |
      栏目导航 网站首页>>科研动态>>国际研究
  发表日期:2014年4月14日        编辑:天明   有2038位读者读过此文 【字体:  
 
 

百健艾迪血友病A药物Eloctate后期度获得成功

(路透社消息)百健艾迪与Swedish Orphan Biovitrum,血液疾病药物Eloctate在一项治疗儿童血友病的后期试验中有效。这款药物在治疗儿童血友病A时能保持较低的出血率。

这项后期试验在之前有过治疗的12岁以下严重血友病A儿童中对Eloctate进行了测试。

Eloctate是一种长效血友病治疗药物,作为预防性注射,患者每两周用药一次。
为预防出血发作,血友病药物通常需要每两天或三天输注一次。

百健艾迪与Swedish Orphan Biovitrum还共同开发了另一款血友病药物Alprolix,这款药物于上个月被FDA批准用于治疗血友病B。血友病B由因子IX缺乏引起。
原文:

(Reuters) - Biogen Idec Inc and Swedish Orphan Biovitrum said their experimental blood disorder drug was effective in treating children with hemophilia in a late-stage trial.

The drug, Eloctate, was able to maintain low bleeding rates in children with hemophilia A - a rare genetic disorder in which a person's blood does not clot properly due to missing or reduced levels of a protein called factor VIII.

The late-stage trial tested Eloctate in previously treated children under 12 years with severe hemophilia A.

The main goal of the study was to evaluate the frequency of antibody development that can interfere with the therapy and none were detected.

Eloctate is a long-acting hemophilia treatment that was given to patients as twice-weekly preventive injections.

Hemophilia drugs generally need to be infused every two or three days to prevent bleeding episodes.

Biogen and Swedish Orphan Biovitrum have also developed another hemophilia drug, Alprolix, that was approved by the U.S. Food and Drug Administration last month for treating hemophilia B. Hemophilia B is caused by the absence of the factor IX protein.

Biogen shares were up slightly at $300.92 in premarket trading. They closed at $300.68 on Wednesday on the Nasdaq.



相关专题:

相关信息:
 没有相关信息

相关评论:
 没有相关评论
 
  发表、查看更多关于该信息的评论 将本信息发给好友 打印本页
 


Copyright © 2002-2058 【血友驿站】> All Rights Reserved 主办:山东省血友病病友联谊会 维护:山东省血友关怀工作室

鲁ICP备11017206号  页面执行时间:78.125毫秒 咨询:86-131-81698297 点击这里给我发消息